Status:

COMPLETED

THC Crossover Study

Lead Sponsor:

University of California, San Francisco

Collaborating Sponsors:

Tobacco Related Disease Research Program

Conditions:

THC

Cannabis

Eligibility:

All Genders

21+ years

Phase:

NA

Brief Summary

This is a randomized, crossover study enrolling experienced dual cannabis-tobacco smokers (N=18) to describe the differences in THC and toxicant exposure, examining pharmacokinetic, subjective, and ca...

Detailed Description

Experienced dual cannabis-tobacco smokers will participate in a within-subject crossover study with three blocks: smoked cannabis (purchased by participants from a local dispensary), dry herb cannabis...

Eligibility Criteria

Inclusion

  • Healthy on the basis of medical history and limited physical examination, as described below:
  • Heart rate \< 105 beats per minute (BPM); Systolic Blood Pressure \< 160 and \> 90\*; Diastolic Blood Pressure \< 100 and \> 50\*
  • \*Considered out of range if both machine and manual readings are above/below these thresholds.
  • Current regular user of cannabis who smokes cannabis as joint or blunt at least 3 times a week for past 3 months
  • History of cannabis vaporizer use or willingness to use the vaporizer in the study
  • Current tobacco cigarette use who smokes ≥ 5 cigarettes per day
  • Saliva cotinine ≥ 50 ng/ml
  • Test positive for D-9-tetrahydrocannabinol (THC) at screening and self-report of cannabis use

Exclusion

  • Unstable medical conditions:
  • Heart disease; Uncontrolled hypertension; Thyroid disease (okay if controlled with medication); Diabetes; Hepatitis B or C or Liver disease; Glaucoma; Prostatic hypertrophy
  • Psychiatric conditions:
  • Current or past schizophrenia, and/or current or past bipolar disorder; Adult onset attention deficit hyperactivity disorder (ADHD); Participants with current or past depression and/or anxiety disorders will be reviewed by the study physician and considered for inclusion; History of psychiatric hospitalizations are not exclusionary, but study participation will be determined as per study physician's approval
  • Concurrent regular use of smokeless tobacco or pipes \[occasional users of these products may be enrolled if they agree to abstain from their use during the period of the study\]
  • Medications:
  • Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, dexamethasone, phenobarbital, and other anticonvulsant drugs).; Concurrent use of nicotine-containing medications; Psychiatric medications: current regular use of any psychiatric medications with the exception of Selective Serotonin Reuptake Inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI) and current evaluation by the study physician that the participant is otherwise healthy, stable, and able to participate.
  • Other/Misc. Chronic Health Conditions:
  • Oral thrush; Fainting; Untreated thyroid disease; Other "life threatening illnesses" as per study physician's discretion
  • Pregnancy:
  • Pregnancy (self-reported and urine pregnancy test); Breastfeeding (determined by self-report)
  • Drug/Alcohol Dependence:
  • Alcohol or illicit drug dependence within the past 12 months with the exception of those who have recently completed an alcohol/drug treatment program; Positive toxicology test at the screening visit (THC \& prescribed medications okay); Methadone replacement therapy
  • Concurrent participation in another clinical trial
  • Inability to communicate in English
  • History of marijuana-induced psychosis or paranoia after smoking marijuana
  • Scoring a 2 or higher on the Severity of Dependence Scale for cannabis use
  • Planning to quit smoking or vaping within the next 60 days

Key Trial Info

Start Date :

October 30 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 25 2024

Estimated Enrollment :

14 Patients enrolled

Trial Details

Trial ID

NCT04429568

Start Date

October 30 2020

End Date

June 25 2024

Last Update

July 1 2024

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Zuckerberg San Francisco General Hospital

San Francisco, California, United States, 94110

2

University of California, San Francisco

San Francisco, California, United States, 94143